CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2022

Summary

CVS Health Corporation reported solid revenue growth for the first quarter of 2022, with total revenues increasing by 11.2% year-over-year to $76.8 billion. This growth was primarily driven by strong performance across all segments, including Pharmacy Services and Retail/LTC, bolstered by increased prescription volume, specialty pharmacy growth, and front-store sales. While overall revenue saw a healthy increase, operating income experienced a slight decline of 2.4% to $3.5 billion. This decrease was largely attributable to a significant legal settlement accrual of $484 million related to opioid claims with the State of Florida. Despite this, the company demonstrated effective cost management, with operating expenses as a percentage of revenue remaining stable. The company also returned capital to shareholders through share repurchases and dividends, reflecting confidence in its ongoing operational strength.

Key Highlights

• 1Total revenues increased by 11.2% to $76.8 billion, driven by strong performance across all business segments.
• 2Operating income saw a slight decrease of 2.4% to $3.5 billion, primarily due to a $484 million legal settlement accrual for opioid claims.
• 3Pharmacy Services segment revenues grew 8.6% to $39.5 billion, supported by increased claims volume and specialty pharmacy growth.
• 4Retail/LTC segment revenues increased by 9.2% to $25.4 billion, driven by higher prescription and front-store sales, including COVID-19 test kits.
• 5Health Care Benefits segment revenues rose 12.8% to $23.1 billion, with growth across all product lines and a slight increase in the medical benefit ratio.
• 6The company repurchased approximately $2.0 billion of common stock during the quarter.
• 7Net income attributable to CVS Health increased by 4.0% to $2.3 billion.

Frequently Asked Questions